卵巢癌靶向治疗的潜在新靶点药物研究进展

Potential novel target drugs for anti-ovarian cancer targeted therapies:research advances

分子靶向治疗在恶性肿瘤的治疗中占据着举足轻重的地位。然而,卵巢癌的分子靶向药物研发进度较为缓慢,目前在国外批准上市的用于晚期卵巢癌的分子靶向药物仅有贝伐珠单抗和奥拉帕尼两种,临床应用具有一定的局限性。近年来,卵巢癌分子靶向治疗的基础及临床研究逐渐增多,以E3连接酶、VEGF/VEGFR通路、PD-1/PD-L1通路、IL-6/IL-6R通路、巨噬细胞游走抑制因子等为靶点的新型药物研究取得了一定的进展。本文针对上述靶点介绍了部分靶点药物的研究进展,以期为今后的研究提供参考。

Molecular target therapy plays an important role in the treatment of malignant tumor. But research and development progress is slow on drugs targeting ovarian cancer. Only bevacizumab and olaparib have been approved for treating ovarian cancer by the FDA or the EMA,and their clinical application is limited. In recent years,there have been more and more reports on molecular target therapy of ovarian cancer. Research advances have been made on novel drugs targeting E3 ubiquitin ligase,VEGF/VEGFR signaling pathways,PD-1/PD-L1 signaling pathways,IL-6/IL-6 R signaling pathways and macrophage migration-inhibitory factor. This article briefly summarizes the current progresses in studies of molecular target therapy in ovarian cancer.